The presence of anti-GRP78 antibodies in the serum of patients with colorectal carcinoma: A potential biomarker for early cancer detection

International Journal of Biological Markers

Volumn 29, Issue 4, 2014, Pages e431-e435

  Raiter, Annat ^a   Vilkin, Alexander ^b   Gingold, Rachel ^b   Levi, Zohar ^b   Halpern, Marisa ^c   Niv, Yaron ^b   Hardy, Britta ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c HASHARON HOSPITAL   (Israel)

Author keywords

Anti GRP78; CRC; Diagnosis; Polyps

Indexed keywords

ANTI GLUCOSE REGULATED PROTEIN 78 ANTIBODY; AUTOANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CLINICAL ARTICLE; COLONOSCOPY; COLORECTAL CARCINOMA; COLORECTAL POLYP; CONTROLLED STUDY; DISEASE CLASSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENDER; HUMAN; MALE; SENSITIVITY AND SPECIFICITY;

EID: 84916213034     PISSN: 03936155     EISSN: 17246008     Source Type: Journal    
DOI: 10.5301/jbm.5000086     Document Type: Article

References (18)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5): 277-300.
2. Pandurangan AK. Potential targets for prevention of colorectal cancer: a focus on PI3K/Akt/mTOR and Wnt pathways. Asian Pac J Cancer Prev. 2013; 14(4): 2201-2205.
3. van Rijn JC, Reitsma JB, Stoker J, Bossuyt PM, van Deventer SJ, Dekker E. Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol. 2006; 101(2): 343-350.
4. Duffy MJ, van Rossum LGM, van Turenhout ST, et al. Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper. Int J Cancer. 2011; 128(1): 3-11.
5. De Chiara L, Rodríguez-Piñeiro AM, Rodríguez-Berrocal FJ, Cordero OJ, Martínez-Ares D, Páez de la Cadena M. Serum CD26 is related to histopathological polyp traits and behaves as a marker for colorectal cancer and advanced adenomas. BMC Cancer. 2010; 10(1): 333-342.
6. Wang J, Wang X, Lin S, et al. Identification of kininogen-1 as a serum biomarker for the early detection of advanced colorectal adenoma and colorectal cancer. PLoS ONE. 2013; 8(7): e70519.
7. Choi JW, Liu H, Shin DH, et al. Proteomic and cytokine plasma biomarkers for predicting progression from colorectal adenoma to carcinoma in human patients. Proteomics. 2013; 13(15): 2361-2374.
8. Ni M, Zhang Y, Lee AS. Beyond the endoplasmic reticulum: atypical GRP78 in cell viability, signalling and therapeutic targeting. Biochem J. 2011; 434(2): 181-188.
9. Schönthal AH. Pharmacological targeting of endoplasmic reticulum stress signaling in cancer. Biochem Pharmacol. 2013; 85(5): 653-666.
10. Mintz PJ, Kim J, Do KA, et al. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol. 2003; 21(1): 57-63.
11. Gonzalez-Gronow M, Cuchacovich M, Llanos C, Urzua C, Gawdi G, Pizzo SV. Prostate cancer cell proliferation in vitro is modulated by antibodies against glucose-regulated protein 78 isolated from patient serum. Cancer Res. 2006; 66(23): 11424-11431.
12. Dukes CE. The classification of cancer of the rectum. J Pathol. 1932; 35(3): 323-332.
13. Shao Q, Ren P, Li Y, et al. Autoantibodies against glucoseregulated protein 78 as serological diagnostic biomarkers in hepatocellular carcinoma. Int J Oncol. 2012; 41(3): 1061-1067.
14. Tsunemi S, Nakanishi T, Fujita Y, et al. Proteomics-based identification of a tumor-associated antigen and its corresponding autoantibody in gastric cancer. Oncol Rep. 2010; 23(4): 949-956.
15. Defresne F, Bouzin C, Guilbaud C, et al. Differential influence of anticancer treatments and angiogenesis on the seric titer of autoantibody used as tumor and metastasis biomarker. Neoplasia. 2010; 12(7): 562-570.
16. Duffy MJ, Van Dalen A, Haglund C, et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer. 2003; 39(6): 718-27.
17. Hardy B, Raiter A, Yakimov M, Vilkin A, Niv Y. Colon cancer cells expressing cell surface GRP78 as a marker for reduced tumorigenicity. Cell Oncol (Dordr). 2012; 35(5): 345-354.
18. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014; 370(14): 1287-1297.